On the assumption that MAP is a causative agent in Crohn's disease, the Australian biotechnology company Giaconda is seeking to commercialize a combination of rifabutin, clarithromycin, and clofazimine as a potential drug therapy, called Myoconda, for Crohn's.
subspecies | Mycobacterium tuberculosis | Prunus avium | Mycobacterium smegmatis | Subspecies ''Parantica aglea melanoides'' on Indian Turnsole ''Heliotropium indicum | Subspecies | Subspecies of Galápagos tortoise | Paratuberculosis | Mycobacterium leprae | Subspecies ''C. m. ardesiacus'', lithograph by Joseph Wolf | Mycobacterium ulcerans | Mycobacterium kansasii | Mycobacterium bovis | ''Mycobacterium avium'' complex |